Skip to content

Pre-treatment HIV severity, not HAART associated with peripheral neuropathy

HIV-related diabetes: a complex interaction between liver damage, body mass and genetics?

Rates of TB treatment interruption unaffected by HIV infection or HAART

Risk factors for gynaecomastia include hepatitis C, fat loss, and low testosterone

ICAAC: Fall in immune cells predicts reaction to abacavir, and high incidence of reaction if abacavir used during primary infection

ICAAC: Mitochondrial DNA level in blood may provide early warning of lipodystrophy

Treatment interruption results in lipid reduction; IL-2 has no effect on lipids

Drug side-effects place treatment scale up at risk, says Ugandan HIV expert

AZT & d4T damage fat cells long before fat loss visible